WSW, NY, March 19th, 2026, FinanceWire
For decades, the treatment of anaphylaxis has been built around a single assumption: that intramuscular injection is the fastest and most reliable way to deliver epinephrine in an emergency.
Nasus Pharma’s (NYSE:NSRX) latest Phase 2 data directly challenges that assumption.
In a 50-subject study, its investigational intranasal powder, NS002, reached therapeutic epinephrine levels in a median of 1.69 minutes – nearly twice as fast as EpiPen, which reached the same threshold in 3.42 minutes. This difference was not only clinically meaningful, but statistically significant.
More importantly, the advantage was most pronounced in the earliest and most critical moments following administration. At just 2.5 minutes, approximately 67% of participants receiving NS002 had already reached therapeutic levels, compared to only 27% of those receiving EpiPen – a statistically significant difference. By 5 minutes, NS002 maintained a clear and statistically significant lead.
In anaphylaxis, these early minutes are often the difference between rapid stabilization and clinical deterioration. Viewed through that lens, the topline results reinforce a clear and consistent signal: NS002 delivers epinephrine faster than the current standard of care.
Understanding the Full Dataset
With that central finding established, the broader dataset provides important context.
As is common in clinical development, the transition from interim to topline results introduces a larger population and, with it, modest numerical differences across certain parameters. In the case of epinephrine, these shifts are not only expected — they are well documented.
Epinephrine is one of the most variable molecules in pharmacology, with widely reported differences across individuals, delivery methods, and study conditions. Importantly, this variability is not unique to investigational therapies; it is observed across approved products, including intramuscular autoinjectors.
In the Phase 2 study, small changes in metrics such as peak timing or the percentage of participants reaching a therapeutic threshold were observed across both NS002 and EpiPen arms. This parallel movement is a key signal. It reflects inherent variability in the molecule rather than any change in the relative performance between treatments.
And across all analyses, the core outcome remained unchanged: NS002 consistently outperformed EpiPen in reaching therapeutic levels during the critical early window, with statistical significance confirmed in the expanded 50-subject dataset.
Speed as the Defining Metric
The topline results place particular emphasis on time to therapeutic threshold — widely considered the most clinically relevant pharmacokinetic endpoint in anaphylaxis.
NS002 achieved the 100 pg/mL plasma level in a median of 1.69 minutes, compared to 3.42 minutes for EpiPen. The separation between treatments was statistically significant and consistent across early timepoints.
This early advantage is critical. In anaphylaxis, the first few minutes following symptom onset represent a narrow window where rapid pharmacologic intervention can prevent escalation and improve outcomes.
Across this window, NS002 demonstrated both faster absorption and greater early drug exposure, reinforcing its potential to deliver meaningful clinical benefit when it is needed most.
A Balanced Pharmacokinetic Profile
The evolution of peak plasma concentration (Cmax) between interim and topline analyses offers additional insight into the overall profile of NS002.
While earlier data suggested higher peak levels, the topline results indicate a profile that is broadly comparable to intramuscular injection. In the context of epinephrine delivery, this represents a potential advantage, aligning with the goal of achieving rapid therapeutic levels without excessive peak exposure.
An optimal epinephrine therapy is not defined by the highest peak concentration, but by how efficiently it reaches therapeutic levels while maintaining controlled systemic exposure. From both clinical and regulatory perspectives, a combination of rapid onset and comparable peak levels represents a balanced and desirable profile.
NS002 appears to achieve that balance.
Performance Under Real-World Conditions
The Phase 2 study design further strengthens the relevance of these findings. Participants were evaluated under both standard conditions and nasal allergic challenge, simulating the physiological environment during an actual allergic reaction.
Even under these more demanding conditions, NS002 maintained its pharmacokinetic advantages over EpiPen, including in repeat dosing scenarios.
This consistency is particularly important. In real-world anaphylaxis, patients may require multiple doses, and physiological conditions are rarely ideal. Demonstrating reliable performance across these scenarios supports the potential for practical, real-world use.
A Consistent and Compelling Signal
Taken together, the data suggests more than incremental improvement.
Across all clinically relevant early timepoints, NS002 outperformed EpiPen in reaching effective epinephrine levels, with statistical significance supporting the difference in time to therapeutic threshold.
As Nasus Pharma advances toward its planned pivotal study, the Phase 2 results provide a clear and consistent narrative: NS002 delivers epinephrine rapidly, reaches therapeutic levels faster than the current standard of care, and maintains performance across conditions designed to reflect real-world use.
In a clinical setting defined by urgency, that combination of speed and reliability may ultimately define the next standard in anaphylaxis treatment.
Read this Next>> Serina Therapeutics Stock Surges Over 39% After Hours— Here’s Why (NYSE:SER)
Latest News Highlights from Nasus Pharma
Nasus Pharma Announces Closing of $15.0 Million Private Placement
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Any referenced price targets are solely the views of the respective respective analysts and do not represent the views of Wall Street Wire or the issuer. Such opinions are subject to the assumptions, risks, limitations, and disclosures contained in the full analyst reports, which readers are encouraged to review in their entirety. Wall Street Wire receives cash compensation from Nasus Pharma Ltd for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article has not been reviewed or approved by the issuer prior to publication and should not be considered an official communication of the issuer.